The entrepreneurial spirit, external focus and pipeline strength transitions Lupin in the UK from standard generics through to a more specialist organisation partnering with the NHS to deliver value.
Lupin Healthcare is a subsidiary of the global pharmaceutical company Lupin Limited, who have a strong heritage in generic medicines. Today’s portfolio consists of Respiratory and Neuromuscular medicines and high quality generics with a focus on anti-retroviral treatments and oral contraceptives.
in 2025 Renascience Pharma Ltd became an afiliate of Lupin Healthcare. Renascience focuses on three key therapy areas: Infectious Disease, Pain Management, and Cardiovascular & Renal Medicine, supporting both primary and secondary care with niche, specialty products that address unmet patient needs.
Generics
HIV anti-retrovirals and oral
contraceptives are key generic
products in the UK with a future
focus on more complex generics
and biosimilars.
Neuroscience
Lupin have launched a medicine
for a rare neurological condition. Further developments in neurology are underway.
Respiratory
Strong Respiratory R&D expertise with products filed to deliver a broad respiratory portfolio for the future.
Infectious
Disease
Renascience provides branded injectable antibiotics used in hospital settings to treat serious infections, with a focus on ensuring reliable access to essential, often hard-to-source medicines.
Pain
Management
Through its focus on acute pain management, Renascience aims to deliver effective, localised relief while improving patient comfort and adherence in everyday care.
Cardiovascular &
Renal Medicine
Renascience is committed to supporting patients with cardiovascular and kidney-related conditions through established oral therapies, helping to maintain continuity of care and improve outcomes in chronic disease management.
